Pharma Services Network

pharmaservicesnet.com

Since 2003, Pharma Services Network has been helping pharmaceutical, biotech, and device sponsors from around the world to identify, qualify, and engage with service providers ideally suited to their needs. We have in-depth knowledge of Internationally based CROs, Regulatory Consultants, and a host of other strategic service providers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

news image

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More

Business Insights

AMPLICORE, INC. ANNOUNCES US FDA CLEARANCE OF FIRST INVESTIGATIONAL NEW DRUG APPLICATION (IND) AND ADDITION OF EXPERIENCED FINANCIAL LEADER TO BOARD

Amplicore, Inc. | July 15, 2022

news image

Amplicore Inc., a Mason, OH-based, early-stage biopharmaceutical company specializing in the development of minimally invasive therapeutic solutions for musculoskeletal disorders, today announced that the Food and Drug Administration has cleared their first application for AM3101, a novel treatment to promote healing of acute meniscal tears. The move enables the initiation of a Department of Defense-sponsored phase 1/2b clinical study in concert with the University of Cincinnati. ...

Read More

EMOTET REEMERGES WITH MASSIVE CAMPAIGN TARGETING PHARMA INDUSTRY

HealthITSecurity | January 20, 2020

news image

Proofpoint is urging all organizations to take steps to shore up any vulnerabilities, after detecting a massive Emotet campaign targeting the pharmaceutical industry. The hacking group behind Emotet is known as TA542. Emotet is a modular botnet able to download and install a wide range of malware. It's also known to steal data and send malicious emails from victims. Proofpoint notes that it can easily spread across networks, leveraging infected devices to launch additional attacks. The notor...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

news image

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More
news image

ANDA APPROVES GLENMARK PHARMACEUTICALS FOR SIROLIMUS TABLETS, 0.5 MG, 1 MG AND 2 MG

Glenmark Pharmaceuticals Inc | October 19, 2020

Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV. According to IQVIATM sales data for the 12 month period ending August 2020, the Rapamune® Tablets, 0.5 mg, 1 mg and 2 mg market2 achieved annual sales of approximately $119.7 million*. Glenmark's current portfolio consists ...

Read More
news image

Business Insights

AMPLICORE, INC. ANNOUNCES US FDA CLEARANCE OF FIRST INVESTIGATIONAL NEW DRUG APPLICATION (IND) AND ADDITION OF EXPERIENCED FINANCIAL LEADER TO BOARD

Amplicore, Inc. | July 15, 2022

Amplicore Inc., a Mason, OH-based, early-stage biopharmaceutical company specializing in the development of minimally invasive therapeutic solutions for musculoskeletal disorders, today announced that the Food and Drug Administration has cleared their first application for AM3101, a novel treatment to promote healing of acute meniscal tears. The move enables the initiation of a Department of Defense-sponsored phase 1/2b clinical study in concert with the University of Cincinnati. ...

Read More
news image

EMOTET REEMERGES WITH MASSIVE CAMPAIGN TARGETING PHARMA INDUSTRY

HealthITSecurity | January 20, 2020

Proofpoint is urging all organizations to take steps to shore up any vulnerabilities, after detecting a massive Emotet campaign targeting the pharmaceutical industry. The hacking group behind Emotet is known as TA542. Emotet is a modular botnet able to download and install a wide range of malware. It's also known to steal data and send malicious emails from victims. Proofpoint notes that it can easily spread across networks, leveraging infected devices to launch additional attacks. The notor...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

VINCERX PHARMA PRESENTS PRECLINICAL DATA ON VIP943 IN ACUTE MYELOID LEUKEMIA MODELS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING 2022

Vincerx Pharma, Inc. | December 12, 2022

Vincerx Pharma, Inc. a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022. VIP943 is a novel ADC, which binds to the IL3-receptor alpha chain . VIP943 co...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us